Aeolus Pharmaceuticl (AOLS) 0.2371 $AOLS
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
Marketwired - Thu Jan 08, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that it has filed a formal mitigation response to the Division of Medical Imaging Products ("DMIP"
of the U.S. Food and Drug Administration ("FDA" after consultation with its development partner, the Biomedical Advanced Research and Development Authority ("BARDA" . The response addresses the questions cited by the DMIP when it placed a clinical hold on the Investigational New Drug Application ("IND" for the testing of AEOL 10150 in healthy human volunteers in September 2014. The healthy volunteer safety studies are part of the Lung Acute Radiation Syndrome ("Lung-ARS" Medical Countermeasure ("MCM" program funded by BARDA under a five-year contract worth up to $118.4 million. BARDA is the division of the U.S. Department of Health and Human Services responsible for the advanced development of MCM for chemical, biological, radiological and nuclear threats.
Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
Marketwired - Tue Dec 30, 7:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the OneMed Forum SF 2015 Conference on Tuesday, January 13, 2015 at 10:50 AM PST (2:50 PM EST) at the Marriott Marquis in San Francisco.
Aeolus posts lower fiscal 2014 net loss of USD80,000
M2 - Tue Dec 23, 5:32AM CST
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) stated on Monday that its net loss was USD80,000 for the fiscal year ended 30 September 2014.
Aeolus Announces Fiscal Year 2014 Financial Results
Marketwired - Mon Dec 22, 4:16PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2014.
Aeolus files international patent for AEOL 10150 covering synthesis, formulation and pharmaceutical composition
M2 - Thu Dec 04, 6:07AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL 10150.
Aeolus Files International Patent Application for New Patent on AEOL 10150
Marketwired - Wed Dec 03, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Tue Dec 02, 10:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that John McManus, Chief Executive Officer, will present at the LD Micro Invitational Conference on Thursday, December 4th, 2014 at 9:00 AM PST (12:00 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. McManus will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA" . The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS" following a nuclear event.
Small Cap Profiles
ACCESSWIRE - Tue Dec 02, 9:38AM CST
NV5 Holdings: A Diversified & Growing Play on Infrastructure
NVEE: 12.60 (+0.05), FIS: 66.52 (+0.33), TSS: 37.09 (+0.17), HIL: 3.79 (+0.03), EBAY: 56.47 (+1.73), FISV: 78.70 (+0.25), TTEK: 24.58 (+0.08), GTIM: 8.23 (+0.07), CMG: 674.89 (+4.60)
Aeolus Announces Presentation of Efficacy Data for AEOL 10150 in Multiple Studies Showing Significant Survival Improvement and Tissue Protection After Radiation Exposure to the Lungs
Marketwired - Mon Oct 20, 6:01AM CDT
-- Data Reported in Presentation and Posters at the 60th Annual Meeting of the Radiation Research Society
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:32AM CDT
Tetraphase Pharmaceuticals, (TTPH) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
LCI: 57.78 (-0.91), TTPH: 35.18 (-0.73), HPTX: 26.83 (-0.05)
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
VSTM: 7.93 (-0.44), LLY: 70.56 (+0.03), EGRX: 20.98 (+1.45)
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwire - Thu Sep 04, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced results from a large study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent -- doubling survival at 180 days after radiation exposure to the lungs. The survival data was presented at an In Process Review ("IPR" meeting with the Biomedical Advanced Research and Development Authority ("BARDA" yesterday. The study results will be included in a pre-Emergency Use Authorization ("EUA" submission to the FDA.
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
Marketwire - Wed Aug 20, 12:00PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of Medical Imaging Products of the US Food and Drug Administration (FDA) to enable the initiation of a phase 1 study of AEOL 10150 in healthy human volunteers. The new phase 1 study is designed as the first step in meeting the requirements for approval of the drug as a medical countermeasure for lung damage due to radiation exposure (Lung-ARS) under the FDA's "Animal Rule." Aeolus is developing AEOL 10150 for this indication under a five-year contract with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $118 million.
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
Marketwire - Fri Aug 15, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and nine months ended June 30, 2014.
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
ADHD: 6.92 (+0.73), AERI: 27.91 (+0.14), ARIA: 7.35 (+0.45)
Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:32AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
SGYP: 2.98 (unch), JAZZ: 169.69 (+6.89), AERI: 27.91 (+0.14)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
Marketwired - Thu Jan 08, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that it has filed a formal mitigation response to the Division of Medical Imaging Products ("DMIP"
of the U.S. Food and Drug Administration ("FDA" after consultation with its development partner, the Biomedical Advanced Research and Development Authority ("BARDA" . The response addresses the questions cited by the DMIP when it placed a clinical hold on the Investigational New Drug Application ("IND" for the testing of AEOL 10150 in healthy human volunteers in September 2014. The healthy volunteer safety studies are part of the Lung Acute Radiation Syndrome ("Lung-ARS" Medical Countermeasure ("MCM" program funded by BARDA under a five-year contract worth up to $118.4 million. BARDA is the division of the U.S. Department of Health and Human Services responsible for the advanced development of MCM for chemical, biological, radiological and nuclear threats. Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
Marketwired - Tue Dec 30, 7:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the OneMed Forum SF 2015 Conference on Tuesday, January 13, 2015 at 10:50 AM PST (2:50 PM EST) at the Marriott Marquis in San Francisco.
Aeolus posts lower fiscal 2014 net loss of USD80,000
M2 - Tue Dec 23, 5:32AM CST
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) stated on Monday that its net loss was USD80,000 for the fiscal year ended 30 September 2014.
Aeolus Announces Fiscal Year 2014 Financial Results
Marketwired - Mon Dec 22, 4:16PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2014.
Aeolus files international patent for AEOL 10150 covering synthesis, formulation and pharmaceutical composition
M2 - Thu Dec 04, 6:07AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL 10150.
Aeolus Files International Patent Application for New Patent on AEOL 10150
Marketwired - Wed Dec 03, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Tue Dec 02, 10:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that John McManus, Chief Executive Officer, will present at the LD Micro Invitational Conference on Thursday, December 4th, 2014 at 9:00 AM PST (12:00 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. McManus will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"
. The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS" following a nuclear event. Small Cap Profiles
ACCESSWIRE - Tue Dec 02, 9:38AM CST
NV5 Holdings: A Diversified & Growing Play on Infrastructure
NVEE: 12.60 (+0.05), FIS: 66.52 (+0.33), TSS: 37.09 (+0.17), HIL: 3.79 (+0.03), EBAY: 56.47 (+1.73), FISV: 78.70 (+0.25), TTEK: 24.58 (+0.08), GTIM: 8.23 (+0.07), CMG: 674.89 (+4.60)
Aeolus Announces Presentation of Efficacy Data for AEOL 10150 in Multiple Studies Showing Significant Survival Improvement and Tissue Protection After Radiation Exposure to the Lungs
Marketwired - Mon Oct 20, 6:01AM CDT
-- Data Reported in Presentation and Posters at the 60th Annual Meeting of the Radiation Research Society
Tetraphase Pharmaceuticals (TTPH) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:32AM CDT
Tetraphase Pharmaceuticals, (TTPH) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
LCI: 57.78 (-0.91), TTPH: 35.18 (-0.73), HPTX: 26.83 (-0.05)
Global Malignant Mesothelioma Therapeutics Pipeline Review 2014 - 11 Companies & 25 Companies
M2 - Fri Sep 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qjk7h/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Deciphera Pharmaceuticals, LLC - Eagle Pharmaceuticals Inc. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - BNC-105 - FPI-01 - YS-110 - BIW-8962 - Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - ONCOS-102 - Drug For Mesothelioma - Oshadi D Oshadi R - AEOL-10150 - anetumab ravtansine - LY-3023414 - Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - VS-4718 - VS-5584 - BERTA - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Ad5-SGE-REIC/Dkk3 Gene Therapy - pemetrexed disodium - Vaccine For Cancer - YP-223 - YYP-218 - YP-3 - DP-3975 - Tb-535C - SentoClone For more information visit http://www.researchandmarkets.com/research/8qjk7h/malignant
VSTM: 7.93 (-0.44), LLY: 70.56 (+0.03), EGRX: 20.98 (+1.45)
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwire - Thu Sep 04, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced results from a large study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent -- doubling survival at 180 days after radiation exposure to the lungs. The survival data was presented at an In Process Review ("IPR"
meeting with the Biomedical Advanced Research and Development Authority ("BARDA" yesterday. The study results will be included in a pre-Emergency Use Authorization ("EUA" submission to the FDA. Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
Marketwire - Wed Aug 20, 12:00PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of Medical Imaging Products of the US Food and Drug Administration (FDA) to enable the initiation of a phase 1 study of AEOL 10150 in healthy human volunteers. The new phase 1 study is designed as the first step in meeting the requirements for approval of the drug as a medical countermeasure for lung damage due to radiation exposure (Lung-ARS) under the FDA's "Animal Rule." Aeolus is developing AEOL 10150 for this indication under a five-year contract with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $118 million.
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
Marketwire - Fri Aug 15, 6:02AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and nine months ended June 30, 2014.
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
ADHD: 6.92 (+0.73), AERI: 27.91 (+0.14), ARIA: 7.35 (+0.45)
Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:32AM CDT
Jazz Pharmaceuticals Public Limited Company (JAZZ) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
SGYP: 2.98 (unch), JAZZ: 169.69 (+6.89), AERI: 27.91 (+0.14)
